Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
- STAIRWAY trial shows sustained efficacy of faricimabon May 11, 2020 at 2:37 pm
A with faricimab has the potential to reduce vascular destabilization in age-related macular degeneration, achieving sustained efficacy with a significantly lower frequency of administration as ...
- VisionCare, Inc. Announces CE Mark Approval of the Tsert-SI™ Delivery System for the CentraSight Treatment Programon May 11, 2020 at 8:08 am
VisionCare, Inc. announces that receipt of a Conformité Européene (CE) Mark for the Tsert-SI™ delivery system for the CentraSight treatment program ...
- Network meta-analysis finds little difference among anti-VEGF regimens for wet AMDon May 11, 2020 at 7:38 am
VEGF agents, dosing and injection frequency for the treatment of neovascular age-related macular degeneration found comparable outcomes for all included anti-VEGF regimens, according to a presenter at ...
- Global Pipeline Drug Forecasts for Age-Related Macular Degeneration - ResearchAndMarkets.comon May 8, 2020 at 2:00 am
Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration of the macula, which is the oval-shaped area of the retina that is responsible for central ...
- Could Sanofi and Regeneron's Dupixent also treat age-related macular degeneration?on May 7, 2020 at 5:15 am
Sanofi and Regeneron’s Dupixent has become a popular treatment for atopic dermatitis and asthma. Now, a research team in Japan has discovered that IL-4 and its receptor—which Dupixent inhibits—could ...
- Insights into the Macular Degeneration Treatment Market to 2025 - Growth, Trends and Forecaston May 6, 2020 at 7:45 am
The "Macular Degeneration Treatment Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The macular degeneration treatment market was ...
- Potential New Drug Target for Age-Related Macular Degenerationon May 6, 2020 at 5:00 am
Scientists have identified an unexpected player in the immune reaction gone awry that is involved in age-related macular degeneration.
- Juvenile Macular Degeneration (JMD) Market 2020 Analysis and Precise Outlook 2030on May 5, 2020 at 11:26 am
Juvenile Macular Degeneration (JMD) Market Insights, Epidemiology, and Market Forecast-2030: The Juvenile Macular Degeneration (JMD) market report provides current treatment practices, emerging drugs, ...
- Study finds unexpected suspect in age-related macular degenerationon May 5, 2020 at 9:32 am
Scientists have identified an unexpected player in the immune reaction gone awry that causes vision loss in patients with age-related macular degeneration (AMD), according to a new study published ...
- Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH studyon May 5, 2020 at 8:35 am
This study aims to quantify the diagnostic test-accuracy of three visual function self-monitoring tests for detection of active disease in patients with neovascular age-related macular degeneration ...
via Google News and Bing News